Lyell Immunopharma (NASDAQ:LYEL) Hits New 1-Year High – What’s Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $25.59 and last traded at $25.46, with a volume of 93527 shares. The stock had previously closed at $22.31.

Analyst Ratings Changes

A number of research analysts have recently commented on LYEL shares. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Monday, September 1st. HC Wainwright reaffirmed a “neutral” rating and set a $20.00 price target (up previously from $10.00) on shares of Lyell Immunopharma in a research note on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lyell Immunopharma presently has an average rating of “Reduce” and an average target price of $20.00.

Lyell Immunopharma Stock Performance

The company’s fifty day moving average price is $18.18 and its 200-day moving average price is $13.25. The stock has a market cap of $540.21 million, a P/E ratio of -1.11 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.81) by $0.68. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. Analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new position in Lyell Immunopharma during the 2nd quarter worth $94,000. Bridgeway Capital Management LLC purchased a new stake in Lyell Immunopharma in the second quarter valued at about $159,000. Clarius Group LLC raised its stake in Lyell Immunopharma by 4.3% in the third quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after buying an additional 820 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Lyell Immunopharma by 107.0% in the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after acquiring an additional 10,768 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Lyell Immunopharma during the second quarter worth about $258,000. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.